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ABSTRACT 
 
JOHN CAREY FITZPATRICK: EXPLORATION OF CANNABINOID AND OPIOID 
AGENTS FROM PLANTS USED IN TRADITIONAL MEDICINE  
 (Under the direction of Dr. Stephen Cutler) 
 
 
Ten plants, with known medicinal uses, were gathered to study for their possible 
production of secondary metabolites that act as opioid and cannabinoid agents. All plants 
were subjected to in vitro bioassays testing for their affinity for the opioid and 
cannabinoid receptors. Banisteriopsis caapi extracts displayed the greatest affinity for 
both opioid and cannabinoid receptors. B. caapi  extracts underwent column fractionation 
yielding fractions that were subjected to further in vitro studies. We discovered that the 
ethanolic extract of this plant (foliage) binds to all three opioid receptors (µ, κ and δ) and 
cannabinoid receptors (CB1 and CB2) with values ranging from 60-90% displacement of 
the respective radioligands for these receptors. Based on the polarity, we observed that 
the highest percent of radioligand displacement was noted in the 50:50 hexanes:ethyl 
acetate fraction on CB1, CB2 and δ-opioid receptors with values of 86.0, 86.9 and 79.3, 
respectively.  
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Background 
I. Contributions of Bioactive Natural Products to Drug Discovery  
Nature has always been a great resource for human advancement. Throughout 
history, humans have experimented with natural products to produce many different types 
of goods such as perfumes, spices, and even medicinal remedies. Natural products, or 
secondary metabolites derived from natural sources, have been a significant resource for 
the development and production of pharmaceutical compounds (Corrado, 2012). From 
1981-2002, 67% of drugs developed worldwide were derived from bioactive natural 
products or mimics of those products (Cragg, 2006). Within the same time period, 70% 
of anti-infective drugs were naturally derived, while 67% of anticancer drugs were also 
naturally derived or inspired from a natural product leads (Cragg, 2006).  
Although there is some recent sentiment from the scientific community that the 
future of medicinal chemistry lies in synthetically produced compounds, there is still 
much value to be appropriated from natural products. Despite secondary metabolites 
sharing similar size, structure, functional groups, orientation and stereochemical 
complexity as synthetic compounds, they alternatively are much more economical to 
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produce than their synthetic counterparts (Cragg, 1997). It is both economically 
infeasible and difficult to implement chemical synthesis of compounds that require large-
scale multistep reactions to produce synthetic equivalents to the naturally occurring 
secondary metabolites (Corrado, 2012). Therefore, using the more economical naturally 
occurring material to conduct the research to isolate and structurally elucidate the 
metabolites is a better use of financial resources. Additionally, nature provides a wide 
array of chemical templates that are far beyond the imagination of most organic chemists.  
Finding bioactive compounds that can be used for pharmacological and medicinal 
purposes is the main goal in natural product research. In the past, natural product 
chemists limited the scope of their work to the isolation and structural elucidation of 
secondary metabolites due to the lack of communication with biologists studying animal 
and plant species. For example, biologists have described about 40,000 species of spiders 
yet less then 1% of their venoms have been investigated (Cragg, 1997). In recent times, 
the increased communication between biologists and chemists studying natural products 
has led to the development of the bioassay-guided approach to isolation and structural 
elucidation of secondary metabolites (Cragg, 2006). This new field has exponentially 
grown the number of pharmacologically significant metabolites elucidated. Most ancient 
remedies that have been in use dating back as far as 2800 BC have sense been 
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investigated for their secondary metabolites. A good example of a discovery resulting 
from the collaboration between the biologists and chemists are the Ginkgo biloba 
extracts.  
The Ginkgo biloba tree, which ancient Chinese culture used as a remedy for 
lethargy, memory loss, mental fuzziness, and vertigo, has been extensively studied and is 
now known to contain ginkgolides that have shown to be antagonists of platelet 
aggregation factor (Cragg, 1997). Ginkgo biloba tree extracts have shown in vitro study 
results producing neuroprotective effects associated with the extracts’ antioxidant 
properties of their flavonoid constitutes as well as the extracts’ ability to inhibit nitric 
oxide-stimulated protein kinase C activity (Bastianetto, 2000). The extracts also exhibited 
possible uses in neurodegenerative diseases such as Alzheimer’s disease through the 
inhibition of amyloid-β-induced apoptosis in neuroblastoma cells (Wu, 2006). The major 
components present in the Ginkgo biloba are shown in Figure 1.   
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Chemical structures of ginkgolides 
Figure 1 
 
Much like the discovery of the G. biloba tree extracts, our research targets active 
compounds from plants used in traditional medicine. Many sources such as plants, marine 
and microbial organisms have been tested through bioassay-guided fractionation 
ultimately leading to purification of the active compounds within the samples. Any active 
compounds that have significant in vivo results in animal models may later be used for 
drug development leading to clinical trials (Cragg, 2006). Although this bioassay guided 
approach has led to many successful clinical trials the process is tedious and time 
consuming. To improve the efficiency of the bioassay guided approach highthroughput 
screening (HTS), where multiple plants are evaluated at the same time, has been adopted 
O
O
O
R3
R1
O
O
O
O
HO
R2
Ginkgolide A: R1= OH, R2= H,  R3= H
Ginkgolide B: R1= OH, R2= OH, R3= H
Ginkgolide C: R1= OH, R2= OH, R3= OH
Ginkgolide J:  R1= OH, R2= H, R3= OH
Ginkgolide M: R1= H, R2= H, R3= H
	   5	  
by most labs to increase the yield of active compounds. Through this extremely 
sophisticated instrumentation and information technology, laboratories have been able to 
screen massive amounts of compounds leading to significant drug discoveries. Although 
this method has historically increased the output of active compounds, it does not hold 
similarly promising efficacy for the future (Mouhssen, 2013). Over the past few decades 
HTS has experienced diminishing returns leading to a drug development bottleneck.  
A technique, reverse pharmacology, aims to reverse the drug development 
bottleneck. This technique focuses on transdisciplinary exploratory studies and 
development of drug candidate leads stemming from clinical experiences and 
experimental observations (Vaidya, 2007). Taking observations from current preclinical 
and clinical research to better target compound leads in combination with the 
highthroughput screening could dramatically improve the perceived drug discovery 
bottleneck (Mouhssen, 2013). The major downside to reverse pharmacology is the risks 
that are inherent with patient trials being conducted prior to in depth laboratory 
investigation.   
 Past discoveries of secondary metabolites have led to very specific assays 
targeting a single pharmacological use of the natural compound within the samples. 
There are anticancer, antiviral, genotoxicity, hepatotoxicity, anti-inflammatory, 
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immunomodulating, gastroprotective, analgesic, and many more types of biological 
assays (Rahman, 2001). Natural products have been used for several thousand years to 
produce powerful analgesia by binding to specific targets (Soares-Bezerra, 2013). Certain 
ATP-gated ion channels within the P2X channel subfamily are providing convincing 
evidence for their use as pharmacological targets to control both analgesia and 
inflammation (Soares-Bezerra, 2013). In addition to ligand-gated ion channels such as the 
P2X purinergic receptors, G protein coupled receptors, shown in Figure 2, such as the 
opioid and cannabinoid receptors are also providing convincing evidence of powerful 
analgesic effects by blocking the release of pain propagating neurotransmitters 
(Cichewicz, 2003). Based on the evidence showing the usefulness of the cannabinoid and 
opioid receptors as targets for pain modulation, we used cannabinoid and opioid receptor 
bioassays to evaluate the binding affinity of different plant extracts.  
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G protein-coupled receptor 
Figure 2 
 
 
 
II. Opioid and Cannabinoid Receptors Role in Pain Modulation 
 For the past 12,000 years there has been documented use of marijuana from areas 
in Asia to India (Abel, 1979). The hemp plant has been used in many different capacities 
from clothing to medical treatment. It was used to treat a wide array of ailments including 
fevers, sleeping disorders, lack of appetite, headache relief and venereal diseases 
(Mechoulam, 1987). The main psychoactive compound in cannabis is Δ9- 
tetrahydrocannabinol (THC), which was isolated and purified in 1965. The chemical 
structure of THC is shown in Figure 3.  
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Chemical structure of THC 
Figure 3 
 
THC’s discovery sparked interest and research dedicated to determining the 
mechanism by which the compound affected the human body (Welch, 2009). These 
classes of compounds that encompass THC are referred to as the cannabinoids and they 
all use the same mechanism that triggers a physiological response. After much research, 
scientists concluded that there existed neurological receptors infused in some cell types in 
the human body that are now referred to as the cannabinoid receptors (Welch, 2009). The 
discovery of the cannabinoid receptors led to further research investigating other ligands 
that have binding affinities for the cannabinoid receptors. Many compounds, both 
cannabinoids and noncannabinoids, have been discovered to have significant modulation 
of the cannabinoid receptors as agonists and antagonists. The cannabinoid receptors are 
O
H
H
Δ9−Tetrahydrocannabinol
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present in high density in the areas of the brain most associated with emotions, spatial 
judgment, motor function, and perception of time (Glass, 1997).   
 The cannabinoid receptors are categorized into two different subtypes, the CB1 
and CB2 receptor subclasses. The CB1 receptors are found both in the nervous and non-
nervous tissues and is the primary contributor to the central nervous system (CNS) effects 
caused by the cannabinoids (Mackie, 2008). Although the CB1 is found in various types 
of tissue it is most prevalent in nervous tissue at the nerve terminals (Mackie, 2008). The 
CB1 subtype is subject to cannabinoid agonists that contribute to classic symptoms of 
cannabis usage including: treatment of nausea for certain types of cancer patients, 
appetite stimulant, relief for ocular swelling associated with glaucoma, and increased 
motor function in patients with spinal cord ailments (Pertwee, 2006).  
 The CB2 receptor subclass, which has a lot of homology to the CB1 subclass, is 
not primarily located in CNS tissue; it is heavily distributed throughout various immune 
cells (Mackie, 2008). For the past ten years, it was commonly accepted that the CB1 
receptor subclasses were the primary contributor to side effects associated with 
cannabinoid agonists. Recently, a functional presence of CB2 receptors has been studied 
and new conclusions have been proposed (Onaivi, 2006). The CB2 receptors are now 
believed to be contributors to depression and drug abuse related to the cannabinoid 
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agonist. These conclusions have been drawn based on studies showing neuronal CB2 
receptors involved in emesis (Onaivi, 2006). A human study was conducted and a CB2 
gene type, Q63R polymorphism, which affects the immunomodulating properties of the 
CB2 receptor, was abundantly present in subjects who were chronically depressed 
alcoholics (Onaivi, 2006). These new conclusions are shedding light on the possibility 
that the CB2 receptors play a much larger role in responses to cannabinoid agonists.  
 Opium poppy, used for its psychotropic affects, has been widespread and its use 
documented back to antiquity. There is even great speculation amongst anthropologists 
and historians that the great poet Homer mentioned Helen of Troy in the epic The 
Odyssey using opium to drug Odysseus’ friends. Opium was utilized in religious 
ceremonies as a euphoriant, which was traditionally heated and inhaled (Kritikos, 1967). 
It was not until 1806 that the compound in opium responsible for most of the CNS effects 
was isolated and named morphine (Brownstein, 1993). Not long after the discovery of 
morphine, codeine was isolated and structurally characterized from the opium poppy 
(Brownstein, 1993).  
Following the discovery of morphine, an alkaloid and weak base, it began to be 
manufactured in large amounts for medical purposes, particularly for its analgetic effects. 
It was found to be a very addictive drug with high abuse. Researchers were then enlisted 
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to discover a powerful opiate anesthetic such as morphine, but with reduced addictive 
characteristics. Heroin was then developed as a new, non-addictive and more powerful 
substitute to morphine (Brownstein, 1993). However, heroin proved to be extremely 
addictive and was not an adequate replacement for morphine as an anesthetic and 
analgesic. Figure 4 below shows the similarities in heroin and morphine’s chemical 
structures and how chemists designed this potent analgesic agent. 
 
Chemical structure of morphine, heroin, and codeine 
Figure 4 
 
Scientists continued to search for replacements for morphine both in nature and 
through chemical synthesis. In 1939, meperidine was synthesized and was the first opiate 
O
R1O
R2O
H
N
Morphine: R1= H, R2= H  
Heroin: R1= Ac, R2= Ac
Codeine C: R1= Me, R2= H
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discovered to have a different chemical structure to that of morphine (Brownstein, 1993). 
Methadone was later discovered as another opiate with a varying chemical structure to 
that of morphine (Brownstein, 1993). Later, in 1942, the first ever antagonist to opiates 
was discovered and named nalorphine. Nalorphine, as seen in Figure 5, and other opiate 
antagonists were able to reverse the affects of morphine and other opiates while also 
producing considerable analgesia (Brownstein, 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
Chemical structure of nalorphine 
Figure 5 
 
While there were great strides made in the early 20th century in the discovery of 
various types of opiate agonists and antagonists, the mechanism by which these drugs 
functioned as well as the receptors they were targeting was still unknown. In 1973, 
O
R1O
R2O
H
N
Nalorphine
	   13	  
researchers discovered that there were stereospecific opiate binding sites located in the 
central nervous system and that these binding sites were not evenly distributed 
(Brownstein, 1993). The existence of naturally occurring opioid receptors in the human 
body lead scientists to believe that endogenous opiates, neurotransmitters, were the 
primary agonists for these binding sites (Brownstein, 1993). Later, scientists studied the 
neurophysiological and behavioral properties of different opioids observed cross-
tolerance, which is the drugs ability to obstruct withdrawal symptoms after the removal 
of the second drug that the animal was tolerant too, between many of the opiates. From 
these experiments three different subtypes of opioid receptors were discovered: µ, κ, and 
δ receptor subtypes.  
   The µ receptors are located throughout the neuraxis and are most dense in the 
caudate putamen at the base of the telencephalon in the brain (Dhawan, 1996). The µ 
receptors when stimulated by opioid agonists inhibit neurotransmitter release, causing 
muscle contractions. There are two variants of the µ receptors, which differ from each 
other by the presence of an 8-amino acid sequence within the C terminal portion of the 
receptor protein, but no molecular biological investigations have validated these 
conclusions (Dhawan, 1996).  
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The κ receptor subtypes are located in different areas of the brain depending on 
what species of animal is being examined. In the guinea pig the κ receptors are found 
primarily in inner layer of the cerebral cortex, interpeduncular nucleus at the base of the 
mesencephalon, and the substantia nigra also within the mesencephalon (Dhawan, 1996). 
In the rat the highest densities are found in the nucleus accumbens in the basal forebrain, 
dorsal endopiriform nucleus in the piriform cortex, interpeduncular nucleus in the 
midbrain tegmentum, and the claustrum on the underside of the neocortex (Dhawan, 
1996). The function of these receptors includes the regulation of these functions: 
nociception, diuresis, feeding and neuroendocrine secretions, and also lymphoma cell 
immune response (Dhawan, 1996). 
The δ receptor subtypes distribution throughout the nervous system is much more 
limited then the other two subtypes. The δ receptor is found in the olfactory bulb in the 
prosencephalon, neocortex in the cerebral cortex, caudate putamen in the telencephalon, 
and the nucleus accumbens in the basal forebrain. Research performed at the 
ultrastructural level provided evidence that δ receptors are responsible for the inhibition 
of neurotransmitter release from the terminals of primary afferent fibers within the dorsal 
horn of the spinal cord (Dhawan, 1996). These receptor subtypes play an important role 
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in mood driven behavior, respiration, cognitive function, gastrointestinal motility, 
olfaction, motor integration, and analgesia (Dhawan, 1996). 
 The wide and uneven distribution of opioid receptor subclasses indicates that each 
subclass may play a distinct role in agonist response (Mansour, 1987). 
III. Plants of abuse from abroad and their evaluation for affinity to opioid and 
cannabinoid receptors 
 Many natural products have not yet been evaluated for potential drug discovery 
leads, which warrant further investigation. In this research project, species of plants were 
selected for study based on their known use in foreign countries as ancient medicinal 
remedies as well as being abused for their psychotropic effects. Ten different plant 
samples were studied and subjected to extraction. The plant with the greatest binding 
affinity for cannabinoid and opioid receptors based on in vitro radioligand bioassays was 
further fractionated. These fractions were guided by more in vitro radioligand bioassays 
with the ultimate goal of isolating and identifying the active compounds.   
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a) Rhamnus purshiana 
 
                                                              R. purshiana bark  
                                               Figure 6  
 
Rhamnus purshiana, commonly known as Cascara sagrada, belongs to the family 
Rhamnaceae and has been used for many centuries as a laxative and for blood 
detoxication (Anon, 1973). It originates in the Pacific Coast region of Canada from 
British Columbia southward. It also has some prevalence in Southern California (Anon, 
1973). The bark of the plant is dried and used as a common traditional medicine. The 
bark is used extensively for treatment of habitual constipation, but has also been used for 
the treatment of hemorrhoids and other digestive ailments (Anon, 1973). The plant’s bark 
can be taken orally in capsule form or as a tea. Due to its terrible taste if taken in its tea 
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form it can cause acute nausea (Anon, 1973). R. purshiana is extremely useful as a 
laxative because it strengthens the peristaltic muscles that line the intestinal wall allowing 
for easy bowl evacuation with no need for additional laxatives. The chemical constitutes 
of the bark that are responsible for stimulating the peristaltic muscles of the colon are 
hydroxyanthracene derivates particularly anthraquinone glycosides (Anon, 1973). These 
compounds inhibit the absorption of water and electrolytes in the colon and increase the 
dilation pressure, which stimulates peristalsis (Anon, 1973).  
 
b) Arctostaphylos uva-ursi 
 
                           A. uva-ursi leaves 
                                                                   Figure 7 
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A. uva-ursi, commonly known as bearberry leaf, has been used as an herbal remedy 
for the treatment of various lower urinary tract infections including inflammatory 
diseases (Heroutova, 2012). The plant’s leaves have undergone extensive study 
eventually leading to the discovery of its most prevalent constituent, arbutin. This 
constituent, when consumed as an herbal tea, is absorbed by the small intestine and then 
undergoes hepatic conjugation to form hydroquinone (Heroutova, 2012). The use of the 
herbal tea as a medical treatment is widespread in Germany, Poland, Spain, Lithuania, 
Slovenia and Estonia.   
 Bearberry leaves have been used since the middle ages in areas such as Central 
Europe. There is also some literature that supports its use in the “New World” by North 
American Indians (Heroutova, 2012). The plant’s leaves were used for the treatment of 
different diseases including: hydrops, lithiasis, diabetes, gonorrhea, and urinary tract 
diseases. Much of the leaf derivates’ effectiveness as an antimicrobial agent depends the 
solvent used in extraction. For example a 30% ethanol extract in water of A. uva-ursi 
leaves inhibited growth of Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, 
Salmonella typhimurium, Serratia marcescens, and Staphylococcus aureus. Alternatively, 
the 95% ethanol extract showed no inhibition of any microbial bacterial (Heroutova, 
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2012). The A. uva-ursi leaves ability to fight urinary tract infections has been identified 
as the result of the hydroquinone acting as an antibacterial agent (Heroutova, 2012). 
 
c) Acacia xanthophloea 
 
                                              A. xanthophloea roots  
                                                                   Figure 8 
 
Acacia xanthophloea, more commonly known as the yellow fever tree, is a fast-
growing tree originating in southern Africa in areas including: Botswana, Kenya, Malawi, 
Mozambique, Somalia, South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe 
(Csurhes, 2012). The yellow fever tree name originates from the trees tendency to grow 
in African swampland where malaria is prevalent, and its yellow tinted bark (Csurhes, 
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2012). Its uses in Africa have traditionally focused on its aesthetic appeal as it is used as 
an ornamental piece. In some other parts of Africa it is also used as a source of wood for 
fire when dried (Csurhes, 2012). Many of the plants in the genus Acacia produce a 
gummy liquid that the tree uses as a mechanism to prevent water loss in the event that the 
bark of the tree is damaged (Hausfater, 1976). The tree’s healing power was discovered 
when it treated a dying patient of malaria in early 1630 (Achan, 2011). The tree’s bark 
and roots extract known as quinine was discovered to be the compound responsible for 
the plants antimalarial properties (Achan, 2011). Quinine was subsequently exported 
heavily to Europe to be mixed with sugar and water creating Tonic Water, a historically 
popular medicinal remedy (Achan, 2011). Quinine is a crystalline alkaloid that is known 
to have many medicinal properties including antimalarial, antipyretic, analgesic, and anti-
inflammatory (Achan, 2011).        
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d) Verbascum densiflorum 
 
                                           V. densiflorum aerial part 
                                                                   Figure 9 
 
Verbascum densiflorum belongs to the family Scrophulariazeae, which are herbs 
commonly found in Europe (Klimek, 2009). The mullein (V. densiflorum) plant’s aerial 
parts have been widely used as an herbal remedy for inflammation of the upper 
respiratory tract, the common cold, external wounds, bronchitis, and spasmodic cough 
(Klimek, 2009). The plant’s aerial parts also have been used as a mild diuretic and anti-
inflammatory agent for urinary tract infections (Klimek, 2009). The plant also has 
antibacterial and antiviral uses for the treatment of Herpes simplex virus, and influenza 
viruses (Klimek, 2009). There as been much research studying the chemical compounds 
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present in V. densiflorum that are responsible for its expectorant and antimicrobial 
effects. The demulcent, emollient, and expectorant capacities are all described by the 
presence of saponins and mucilage. The antimicrobial, anti-inflammatory, and diuretic 
capabilities are attributed to the two phenolic compounds, phenylethanoids and 
flavonoids (Klimek, 2009).    
 
e) Rubus idaeus 
 
                                                   R. idaeus leaves 
                                                                   Figure 10 
 
Rubus idaeus is more commonly known as red raspberry is part of the family 
Roseaceae that is a native North American species that also grows in northern Asia and 
Europe (Chevallier, 1996). It is a well-known plant because of its edible fruits 
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(Baranowska, 2014). R. idaeus’ leaves have been utilized for medicinal purposes in 
multiple different facets including the treatment of diarrhea, menstrual cramps, tonsillitis, 
mouth sores and inflammations, minor wounds, burns, vomiting, and heart disease 
(Chevallier, 1996). The plant contains several chemical compounds that contribute to its 
antimicrobial and antibacterial properties including a number of phenolic compounds 
such as anthocyanins, ellagitannins, flavonoids, phenolic acids and flavan-3-ols 
(Baranowska, 2014). R. idaeus antimicrobial properties have an inhibitor affect on 
Bacillus subtilis, Clostridium sporogenes, Staphylococcus epidermidis, Neisseria 
meningitides, Moraxella catarrhalis, and Helicobacter pylori (Baranowska, 2014). 
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f) Datura stramonium 
 
                                                D. stramonium seeds 
                                                                    Figure 11 
 
Datura stramonium, commonly known as “Jimson weed”, is a toxic weed that is 
found in the Thirunallar region of Pondicherry, India. The seeds, leaves and stems all 
contain several alkaloid compounds that are recognized as natural poisons (Sridhar, 
2014).  The seeds are the most toxic part of the plant that if consumed in a high enough 
quantity can be fatal. The seeds contain tropane alkaloids that have a strong effect on the 
central nervous system. These tropane alkaloids include atropine, hyoscyamine, and 
scopolamine which all affect the nerve cells in the brain and spinal cord. The components 
within D. stramonium can have an effect on breathing, blood circulation, heartbeat, and 
regulation of internal organs (Sridhar, 2014). 
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g) Hyoscyamus niger 
 
                                                    H. niger seeds 
                                                                   Figure 12 
 
Hyoscyamus niger, commonly known as Henbane, is a plant in the Solanaceae family 
and can be found throughout areas of Europe and Asia (Zhang, 2014). The seeds of the 
H. niger have been used historically in areas of China to treat asthma, cough, colic, 
toothache, inflammation of the pulmonary region, stomach-intestinal pain resulting from 
worm infestation, diarrhea neuralgia, and Parkinson’s disease. It has known effectiveness 
as a therapeutic agent, antispasmodic, sedative, analgesic agent, anthelmintic, antitumor, 
and febrifuge (Zhang, 2014). H. niger’s efficacy as a medicinal remedy stems from its 
chemical constitutes, which includes the tropane alkaloids such as atropine, scopolamine, 
anisodamine. There are other chemical constitutes present as well including tyramine 
alkaloids, withanolides, lignanamides, and flavonoids (Zhang, 2014). The plant can be 
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toxic if excessive doses are taken which results in respiratory paralysis. The tropane 
alkaloids affect acetylcholine-mediated signal transduction by acting as agonists on the 
muscarinic receptors. Being agonists of the muscarinic receptors allows tropane alkaloids 
to be effective therapeutics for treating nausea, diabetes, and act as an antidote for 
poisoning by organophosphorus compounds (Zhang, 2014). 
 
 
h) Nerium oleander 
 
                                              N. oleander aerial part 
                                                                  Figure 13 
 
Nerium oleander, commonly known as Kaner, is part of the family Apocynaceae and 
is native to southern Europe while being naturalized in North America, Europe, and Asia 
(Fartyal, 2014). The plant’s aerial parts have been attributed with chemical constitutes 
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that have medicinal properties such as larvicidal, insecticidal, antimitotic, depressant, 
antifungal, anticancer, antineoplastic, antibacterial, antidiabetic, anti-inflammatory, 
analgesic, and cardiotonic (Fartyal, 2014). N. oleander is useful on the treatment of skin 
problems, warts, menstrual pain, asthma, seizures, cancer, epilepsy, malaria, leprosy, 
ringworm, indigestion, and venereal diseases. The antimicrobial properties of the plant 
can be attributed to its secondary metabolites which include the alkaloids, flavonoids, 
saponins, tannins and phenols chemical constitutes. The flavonoids are particularly 
effective as anticancer agents because of their ability as a free radical scavengers that 
prevents oxidative cell damage (Fartyal, 2014). 
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i) Passiflora caerulea 
 
                                              P. caerulea aerial part 
                                                                  Figure 14 
 
Passiflora caerulea, commonly known as the passionflower of the Passsifloraceae 
family, is native to South America specifically Argentina. The aerial parts of the plant 
have historically been used as a sedative with no myorelaxant effects. The flavonoid, 
chrysin, might be responsible for the anxiolytic effects exhibited by the plant (Busilacchi, 
2002). The plant also has many other medicinal uses including analgesic, adaptogenic, 
antiaging, anti-inflammatory, antispasmodic, antistress, antitussive, and hypotensive 
(Busilacchi, 2002). 
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j) Banisteriopsis caapi 
 
                                                   B. caapi leaves 
                                                                   Figure 15 
 
Banisteriopsis caapi is a hallucinogenic vine originating in the Amazon basin in 
South America that belongs to the Malpighiaceae family (Gibbons, 2013). It is the main 
ingredient in a famous religious healing ceremonial drink known as “ayahuasca,” which 
is a mix of both the B. caapi and Psychotria viridis (Gibbons, 2013). Although the drink 
is primary used in South America, its use in North America and Europe has increased in 
the past few years (Gibbons, 2013). The drink has moved from being the Amazonian 
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indigenous people’s religious drink to being a key component in the “New Age” rituals 
around the Western world (Trichter, 2010).  
The drink is prepared by boiling the leaves of B. caapi and the leaves of P. viridis 
together with other various native South American plants (Gibbons, 2013). The active 
components found in B. caapi are β-carboline alkaloid derivatives, which are harmine, 
harmaline, and tetrahydroharmine (THH) (Gibbons, 2013). The average drink of 
ayahuasca contains 467 mg of harmine, 160 mg of tetrahydroharmine, 41 mg of 
harmaline, and 60 mg of dimethyltryptamine (DMT). The DMT inthe drink is the active 
constituent of P. viridis and is the main psychoactive ingredient of the drink (Gibbons, 
2013). The P. viridis and other additive plants in the drink make up the principle sources 
of active ingredients in ayahuasca, while the B. caapi acts as a monoamine oxidase 
inhibitor by way of β-carboline alkaloids, which makes the tryptamines of the additive 
plants orally active (Winkelman, 2005). The human body naturally produces peripheral 
monoamine oxidase (MAO), which can break down DMT quickly enough so it doesn’t 
reach the central nervous system if taken orally rendering the drink inactive as a 
hallucinogenic. Therefore the ayahuasca drink must be mixed with an MAO inhibitor 
such as B. caapi to allow for the DMT to have the effect above (Gibbons, 2013).     
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 Chemical structure of DMT and tetrahydroharmine 
Figure 16 
 
The three β-carboline alkaloid derivatives of the B. caapi have promising 
prospects as medicinal treatments for neurological disorders (Gibbons, 2013). The 
harmaline and harmine derivatives ability to act as a monoamine oxidase inhibitor 
(MAO) of both –A and –B isozymes present in the brain, indicates the plants ability to 
prevent neuronal cell damage (Gibbons, 2013). Both harmaline and harmine are able to 
stimulate dopamine release within the CNS (Gibbons, 2013). Many neurodegenerative 
disorders such as Parkinson’s disease and Alzheimer’s are in part the result of oxidative 
free radicals damaging neurological cells. Proanthocyanidins found in the B. caapi 
possess antioxidant properties as well as moderate MAO-B inhibitory properties that can 
protect neurological cells from damage by oxidative free radicals (Gibbons, 2013).  
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Chemical structures of harmaline and harmine 
Figure 17 
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Materials and Methods: 
I. General experimental procedures 
1H and 13C Nuclear Magnetic Resonance (NMR) spectra were obtained on Bruker 
model AMX 500 NMR and 400 Avance NMR spectrometers with standard pulse 
sequences, operating at 500 MHz and 400 MHz, respectively in 1H and 100 MHz and 125 
MHz in 13C, respectively. The chemical shift values were reported in parts per million 
units (ppm) from trimethylsilane (TMS) using known solvent chemical shifts. Coupling 
constants were recorded in Hertz (Hz). Standard pulse sequences were used for COSY, 
HMQC, HMBC, TOCSY, NOESY and DEPT. High-resolution mass spectra (HRMS) 
were measured on a Micromass Q-Tof Micro mass spectrometer with a lock spray source. 
Column chromatography was carried out on silica gel (70-230 mesh, Merck), Sephadex 
LH-20 (Mitsubishi Kagaku, Tokyo, Japan). TLC (silica gel 60 F254) was used to monitor 
fractions from column chromatography. Visualization of the TLC plates was achieved 
with a UV lamp (λ = 254 and 365 nm) and anisaldehyde/acid spray reagent (MeOH-
acetic acid-anisaldehyde-sulfuric acid, 85:9:1:5). Solvents were certified grade for 
Fischer Scientific. All chemicals used were purchased from Sigma-Aldrich (St. Louis, 
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Mo) with the following exceptions: for the binding experiments, [3H]-CP-55,940 (144 
Ci/mmol), was purchased from Perkin-Elmer Life Sciences Inc. (Boston, MA, U.S.A.). 
CP-55,940 was purchased from Tocris Bioscience (Ellisville, Missouri, U.S.A.). 
II. Plant material 
The plants Banisteriopsis caapi, Rhamnus purshiana, Arctostaphylos uva-ursi, 
Acacia xanthophloea, Verbascum densiflorum, and Rubus idaeus were all obtained from 
Bouncing Bear Botanicals Company. The plants Datura stramonium, Hyoscyamus niger, 
Nerium oleander, and Passiflora caerulea were all collected in the Quetta region of 
Pakistan in July of 2012 and were identified by Dr. Arsala Mansoor from the Department 
of Biochemistry, Bolan Medical College, Quetta, Pakistan. All plants were separated into 
3 parts the leaves, stem/bark, seeds. The leaves of the B. caapi were investigated, the bark 
of the R. purshiana was investigated, the leaves of the A. uva-ursi was investigated, the 
roots of the A. xanthophloea were investigated, the leaves and stems of the V. 
densiflorum were investigated, the leaves of the R. idaeus were investigated, the seeds of 
the D. stramonium were investigated, the seeds of the H. niger were investigated, the 
leaves and stems of the N. oleander were investigated, and the leaves and stems of the P. 
caerulea were investigated.  
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III. Material Preparation  
 The plant material was sent to our lab in a variety of forms. Some were intact 
leaves and aerial parts, while others were broken down into smaller pieces. To allow for a 
uniform ethanolic extraction all of the plant material was grinded down to a powder. This 
allowed for the greatest surface area to be achieved leading to better ethanolic extraction. 
Each sample of plant material was grinded into powder using a KIKA Werke M20 
grinder, as pictured below in Figure 18. The grinding yielded approximately 110 grams 
per plant.   
KIKA Werke M20 Grinder 
Figure 18 
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IV. Extraction and isolation 
The ten plants were each extracted with 450 ml of ethanol after maceration for 
three days, separately. After removal of the solvent by rotoevaporation a viscous residue 
(crude extract) remained yielding results shown in Table 1.  
 Part of Plant 
Extract Weights 
(grams) 
% Extract 
B. caapi leaves 3.2 2.91% 
R. purshiana bark 3.2 2.91% 
A. uva-ursi leaves 4.7 4.27% 
A. xanthophloea roots 4.9 4.45% 
V. densiflorum aerial part 3.6 3.27% 
R. idaeus leaves 2.5 2.27% 
D. stramonium seeds 4.7 4.27% 
H. niger seeds 3.9 3.55% 
N. oleander aerial part 5.8 5.27% 
P. caerulea aerial part 3.5 3.18% 
Ethanolic extraction results 
Table 1 
The ethanolic extracts from the plants were then subjected to bioassay radioligand 
displacement testing in the cannabinoid and opioid receptor assays. The ethanolic extract 
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from the plants showed varying binding affinity through radioligand displacement on 
cannabinoid receptors (8% - 41%). The extracts radioligand displacement for opioid 
receptors also showed great variability (.5%-79.1% δ, 21.6%-64.96% κ, 9.5%-73% µ.)  
 CB2 % 
Inhibition 
δ %    
Inhibition 
κ %    
Inhibition 
µ %    
Inhibition 
B. caapi 28.8 79.1 64.9 73.0 
R. purshiana -  30.0 -  20.9 
A. uva-ursi 8.0 0.5 - 23.9 
A. xanthophloea - 24.8 - 27.6 
V. densiflorum 41.0 39.7 30.9 42.7 
R. idaeus 27.2 24.9 31.1 - 
D. stramonium 27.1 49.6 21.6 55.5 
H. niger 24.8 27.1 -  9.5 
N. oleander - 14.5 23.1 - 
P. caerulea - 58.9 25.3 48.6 
Radioligand displacement binding affinity of various subtypes 
Table 2 
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V. Cell culture 
HEK-293 cells stably transfected with opioid receptor subtypes µ, δ, and κ were 
used to perform the opioid receptor binding assays. These cells were maintained at 37 °C 
and 5% CO2 in a Dulbecco’s modiﬁed Eagle medium (DMEM) nutrient mixture 
supplemented with 2 mM L-glutamine, 10% fetal bovine serum, penicillin−streptomycin, 
and either G418 or hygromycin B antibiotic solutions. Membranes for the radioligand 
binding assays were prepared by scraping the cells in a 50 mM Tris-HCl buffer, followed 
by homogenization, sonication, and centrifugation for 40 min at 13650 rpm at 4 °C. 
These were kept at -80 °C until used for bioassays. Protein concentration was determined 
via Bio-Rad Protein Assay (Bradford, 1976). 
VI. Radioligand Binding for Cannabinoids and Opioid Receptor Subtypes 
All the extracts, fractions, and pure compounds from B. caapi were run in 
competition binding assays against both cannabinoid receptor subtypes and all three 
opioid receptor subtypes (León et al., 2013). Cannabinoid binding took place under the 
following conditions: 10 µM of each compound was incubated with 0.6 nM [3H] CP 
55.940 and 10 µg of CB1 or CB2 membranes for 90 minutes in a silanized 96-well plate. 
The reaction was terminated via rapid vacuum ﬁltration through GF/B ﬁlters presoaked 
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with 0.3% bovine serum albumin (BSA) using a Perkin-Elmer 96-well Uniﬁlter followed 
by 10 washes with 50 mM Tris-HCl. Plates were read using a Perkin-Elmer Topcount. 
Opioid binding assays were performed under the following conditions: 10 µM of each 
compound was incubated with [3H]-DAMGO (µ), [3H]-U-69,593 (κ), or [3H]-enkephalin 
(δ) for 60 min in a 96-well plate. Percent binding was calculated as the average of the 
triplicate tested at 10 µM. Each sample concentration point of the compounds tested in 
dose response was in triplicate, and each compound showing activity was tested at least 
three times. The reaction was terminated via rapid vacuum ﬁltration through GF/B ﬁlters 
presoaked with 0.3% bovine serum albumin (BSA) using a Perkin-Elmer 96-well 
Uniﬁlter followed by 10 washes with 50 mM Tris-HCl. Plates were read using a Perkin-
Elmer Topcount. Total binding was deﬁned as binding in the presence of 1.0% DMSO. 
Nonspeciﬁc binding was the binding observed in the presence of 10µM DAMGO (µ), 
nor-binaltorphimine (κ), or DPDPE (δ). Speciﬁc binding was deﬁned as the diﬀerence 
between total and nonspeciﬁc binding. Percent binding was calculated using the 
following formula:  (binding of compound - nonspecific binding) x 100/specific binding. 
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VII. Animal Model 
 Adult male Swiss Webster mice (21-24g) were obtained from Harlan 
Laboratories. All animals were housed five to a cage and received food/water ad lib. The 
housing facilities were maintained on a 12 h light/dark schedule (lights on at 6:00 am and 
off at 6:00 pm). Mice were randomly divided into 3 groups (n=10/dose).  
The mouse tetrad is a behavioral assay developed by Martin et al. (1994) to 
characterize the biological effects of cannabinoids using locomotor activity, nociception, 
changes in body temperature, and catalepsy. The assay has been well documented to 
indicate that the typical effects of cannabinoids is decreased in locomotion, and increased 
in cataleptic activity, antinociception, and hypothermia (Pertwee, 2006). Twenty-four 
hours prior to the start of the experiment, mice were acclimated for 15 minute increments 
to the cold hotplate container and apparatus. On the experimental day, mice were brought 
into the experimental room and allowed to acclimate to the room settings for 30 minutes 
and then to the locomotor chamber for 30 minutes. Baseline readings for antinociception 
both spinal (tail-flick) and supraspinal (hotplate), catalepsy, and hypothermia were 
evaluated pre-injection. Animals were injected with either the vehicle 
(ethanol:cremophor:saline in a 1:1:18 ratio) or the test compound (10 mg/kg – 100 
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mg/kg). Animals were then allowed to individually quantify in the locomotor chamber 
(San Diego Instruments) for 30 minutes (expressed as the number of photo-beam breaks). 
The last 10 minutes of quantifying time was used for data analysis. Hotplate and tail-flick 
latencies (using cut off time of 45 seconds and 15 seconds, respectively, to reduce the 
chance of tissue damage), the change in core body temperature (oC) and catalepsy (secs) 
were recorded at 30 minutes post-injection. 
Data was show as mean ± SEM with each group having n = 10 animals. Both 
hotplate and tail-flick were expressed as percent maximum effect (%MPE = [(post-drug 
latency-basal latency)/(cutoff latency-basal latency)] X 100 (Martin et. al., 1994). 
Statistical analysis was performed using one way ANOVA preceded by the Dunnett’s 
post hoc test to define significant difference against the vehicle control at p<0.05. 
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Results and Discussion: 
I. Bioassay-guided Fractionation  
Based on the radioligand displacement results of the bioassay B. caapi, was 
selected for further evaluation. With the aim to get a greater amount of the B. caapi 
extract, the rest of the available plant material was ground into a powder yielding 64.6 
grams. The ground material was then subjected to extraction with 250 ml of ethanol after 
maceration for three days yielding (1.86 g). The ethanolic extracts of B. caapi were all 
combined obtaining (4.5 g) and then chromatographed on Si gel flash column with 
stepwise fractions from hexanes to methanol, yielding eight fractions, which are shown 
with their radioligand displacement binding affinities below in Table 3.  The B. caapi 
fractions were then subjected to bioassay radioligand displacement testing. The results 
showed varying radioligand displacement binding affinity for cannabinoid receptors 
(22.6% - 86% CB1, 26.8% - 86.9% CB2). The extracts radioligand displacement for 
opioid receptors also showed great variability (30.3%-79.3% δ, 6.9%-55.8% κ, 1.5%-
62.9% µ.)  
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 CB1 % 
Inhibition 
CB2 % 
Inhibition 
δ % 
Inhibition 
κ % 
Inhibition 
µ % 
Inhibition 
hexanic fraction (100%; 29mg) 22.6 26.8 - 6.9 1.5 
hex:EtOAc (75:25; 632mg) 37.9 66.7 39.4 29.9 10.5 
hex:EtOAc (50:50; 96mg) 86.0 86.9 79.3 55.8 62.9 
hex:EtOAc (25:75; 64mg) 39.8 64.5 60.8 39.1 35.5 
EtOAc fraction (100%; 58mg) 35.3 54.8 36.3 22.7 17.3 
EtOAc:MeOH (90:10; 484mg) 
34.1 57.3 55.6 25.9 28.6 
EtOAc:MeOH (75:25; 2.17g) 
47.3 51.1 44.2 34.3 39.8 
MeOH fraction (100%; 3.58g) 64.4 43.8 30.3 15.6 19.5 
Radioligand displacement binding affinity of B. caapi fractions 
Table 3 
 
Based on the radioligand displacement results of the bioassay we selected 100% 
hexanes, 75% hexanes in EtOAc, 50% hexanes in EtOAc, and 75% EtOAc in hexanes 
fractions to continue to investigate. The four fractions were submitted to Si gel thin layer 
chromatography (TLC). Dichloromethane (DCM) and methanol were used to dissolve the 
extracts. Various solvents were used in different concentrations to create the systems for 
the TLC plates.  
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TLC: 80% hexanes in EtOAc (1: 100% Hexanes Extract. 2: 75-25% hex:EtOAc. 
3: 50-50% hex:EtOAc. 4: 25-75% hex:EtOAc.)  
Figure 19 
 
TLC: 70% hexanes in EtOAc (1: 100% Hexanes Extract. 2: 75-25% hex:EtOAc. 
3: 50-50% hex:EtOAc. 4: 25-75% hex:EtOAc.) 
Figure 20 
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TLC: 90% DCM in Acetone (1: 100% Hexanes Extract. 2: 75-25% hex:EtOAc. 3: 
50-50% hex:EtOAc. 4: 25-75% hex:EtOAc.) 
Figure 21 
Based on the TLC results we choose fractions 75% hexanes in EtOAc and 50% 
hexanes in EtOAc for additional studies. The two fractions were subjected to a sephadex 
column using a solvent system of hexanes, DCM, and MeOH (1:1:1). Thirty-two 
subfractions were obtained from the 75% hexanes (600 mg) in EtOAc sephadex column 
and were subsequently combined based on the TLC (DCM:MeOH; 9:1). The 50% 
hexanes (500 mg) in EtOAc sephadex column yielded twenty-nine fractions, which were 
subsequently combined based on TLC (DCM:MeOH; 9:1). The subfractions from 75% 
hexanes in EtOAc were combined into two groups, fractions (BC-C-2(1-5), (BC-C-2(10-
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13). The subfractions from 50% hexanes in EtOAc were combined into four groups, 
fractions (BC-C-3(1-5), (BC-C-3(6-9), (BC-C-3(10-12), and (BC-C-3(13-29). 
TLC: 90% DCM in Acetone (1: BC-C-2(13-32). 2: BC-C-2(1-5). 3:BC-C-2(10-
13). 4: BC-C-3(1-5). 5: BC-C-3(6-9). 6: BC-C-3(10-12). 7: BC-C-3(13-29).) 
Figure 22 
These six combined groups of subfractions were submitted to bioassay 
radioligand displacement testing. The results showed varying radioligand displacement 
binding affinity for cannabinoid receptors (2.5%-71.2% CB1, 11.5%-78.1% CB2). The 
extracts radioligand displacement for opioid receptors also showed great variability 
(15.7%-86.7% δ, 11.8%-61.4% κ, 10.2%-45% µ.) The results of the radioligand 
displacement binding affinity are shown below in Table 4. 
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 CB1 % 
Inhibition 
CB2 % 
Inhibition 
δ % 
Inhibition 
κ % 
Inhibition 
µ % 
Inhibition 
BC-C-2(1-5) (102mg) 71.2 69.7 68.3 47.8 39.1 
BC-C-2(10-13) (21mg) 
26.0 30.0 15.7 19.4 - 
BC-C-3(1-5) (18mg) 2.5 26.1 30.7 11.8 10.2 
BC-C-3(6-9) (69mg) 65.6 78.1 86.7 61.4 45.0 
BC-C-3(10-12) (78mg) 38.5 14.1 52.6 - 41.7 
BC-C-3(13-29) (18mg) 28.3 11.5 48.3 - - 
Radioligand displacement binding affinity of B. caapi fractions 
 (BC-C-2 and BC-C-3) 
                                                        Table 4 
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II. Isolation and Purification 
 The BC-C-3(10-13) subfraction showed in the TLC (Figure 22) the presence of a 
major compound with some impurities. It was subjected to 1H NMR NMR spectroscopy 
and the results are shown below in Figure 23.  
 
        1H NMR Spectroscopy of BC-C-3(10-13) 
    Figure 23 
The BC-C-3(10-13) fraction NMR’s was too crude to conclude any results. 
Therefore, the fraction was subjected to additional sephadex column fractionations in an 
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attempt to isolate a major compound. The sephadex column fractionation isolated a single 
active fraction that was subjected to further NMR analysis. The sample was labeled BC-
C-3(10) (1.2 mg) and was subjected to three NMR tests including 1H NMR, 13C NMR, 
and DEPT NMR. The results for those respective NMR’s are seen below in Figures 24-
27.  
 
1H NMR Spectroscopy of BC-C-3(10) 
Figure 24 
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13C NMR Spectroscopy of BC-C-3(10) 
Figure 25 
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13C NMR Spectroscopy of BC-C-3(10) Overlay 
Figure 26 
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DEPT NMR Spectroscopy of BC-C-3(10) 
Figure 27 
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Based on the NMR results for BC-C-3(10) a purified compound, α-Amyrin, was isolated. 
The chemical structure of α-Amyrin, which is based on the comparison of its 1H and 13 C 
NMR data and the reported literature, is shown in Figure 28 (Wehril, 1988).  
 
Chemical Structure of α-Amyrin 
Figure 28 
Further NMR studies will be performed to elucidate the active compounds in BC-
C-2(1-5), BC-C-3(1-5), BC-C-3(6-9), BC-C-3(10-12), and BC-C-3(13-29). Given that 
the amount of each extract is so small isolating the main component within each 
subfraction is the main goal. α-Amyrin is the main compound within subfraction BC-C-
3(10-13), but there are other possible active compounds within the subfraction that could 
be isolated given a greater quantity of extract. More plant material will need to be 
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gathered to further investigate other possible active compounds within subfraction BC-C-
3(10-13) as well as the other subfractions.  
III. Animal Model  
 The hex:EtOAc (50-50) fraction from the B. caapi from Table 3 was selected 
because of its high cannabinoid and opioid receptor binding affinity values and was 
further subjected to a mouse model study to observe the fractions neurological 
interaction. The results for locomotive activity, hotplate latency, catalepsy latency, 
change in rectal temperature, and tail-flick latency testing are shown below in Figures 29-
33 respectively.  
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Locomotive Latency  
Figure 29 
 
Hotplate Latency 
Figure 30 
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Catalepsy Latency 
Figure 31 
 
Change in Rectal Temperature  
Figure 32 
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Tail-Flick Latency 
Figure 33 
The in vivo mouse model study showed no promising results. The test examined 
the fraction’s affect on the central nervous system. Given that the fraction submitted was 
only tested for activity in the central nervous system, there is possible peripheral nervous 
system stimulation that will be investigated in a later study.  
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Conclusion: 
 Traditional medicine has used secondary metabolites derived from natural 
products to treat various medical ailments for thousands of years. Natural products have 
led to numerous drug discoveries and continue to show significant strides towards further 
applications for pain and addiction modulation therapies. In this research we sought to 
evaluate ten different plants’, which were historically used as medical remedies, binding 
affinities for opioid and cannabinoid receptors.  Each plant under went extraction and was 
subjected to preliminary bioassays to determine which plant had the greatest radioligand 
displacement. B. caapi was determined to have the greatest binding affinity for both 
cannabinoid and opioid receptors. The B. caapi  ethanolic extract then underwent silica 
gel column fractionation yielding fractions that were each individually subjected to 
further bioassays. From the bioassay results the fraction hex:EtOAc (50-50) had the 
highest radioligand displacement. A sample of the hex:EtOAc (50-50) fraction was 
submitted to an in-vivo mouse model study to evaluate it’s neurological affects. No 
significant results could be concluded from the mouse model. The hex:EtOAc (50-50) 
fraction was then subjected to further bioassay guided sephadex column fractionations 
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leading to six fractions with significant radioligand displacement to be isolated. One of 
these fractions, BC-C-3(10-13) underwent NMR spectroscopy. The results from that 
NMR led to further sephadex column fractionations, which resulted in a pure compound 
being isolated. This pure fraction, BC-C-3(10), was submitted to three different NMR 
spectroscopy studies which revealed the chemical structure of the fraction known by the 
common name α-Amyrin. The next aim in this study is to investigate the other five 
sephadex column subfractions for the compound that is responsible for the radioligand 
displacement and validate its pain and addiction modulation efficacy. 
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